Vir Biotechnology is a clinical-stage pharmaceutical company that develops treatments and preventive therapies for serious infectious diseases, operating globally from its San Francisco headquarters. Its pipeline includes investigational candidates aimed at hepatitis delta virus and solid tumors, along with earlier-stage programs targeting influenza, coronavirus, and other oncology indications. The company maintains multiple partnerships and licensing agreements with pharmaceutical and research institutions to advance its development programs.

entry readiness 4 · NOT READY · exit proximity 38

Value area 9.28–11.77 · 4% of 120d volume overhead · clean runway